Disclosed is a pharmaceutical composition comprising the following two types of cells: an NK cell and a lymphocyte, or the following three types of cells: an NKT cell, an NK cell and a lymphocyte, all of which are contained in the pharmaceutical composition in the proliferated and activated state. Also disclosed is a method for producing the pharmaceutical composition. The following two types of cells: an NK cell and a lymphocyte, or the following three types of cells: an NKT cell, an NK cell and a lymphocyte can be proliferated and activated almost simultaneously, readily and efficiently, by charging a peripheral blood lymphocyte mixture isolated from a peripheral blood and a lymphocyte culture medium containing interleukin-2 into a culture vessel having both of an anti-human CD3 monoclonal antibody and an anti-human CD161 monoclonal antibody immobilized thereon, and culturing the mixed solution in the culture vessel.
